AbCellera Biologics Inc. filings document regulatory disclosures for a clinical-stage biotechnology company developing antibody-based medicines. Form 8-K reports cover financial and operational results, Regulation FD presentations, ABCL635 clinical program updates, patent settlement and license matters, and leadership or board changes.
Proxy materials describe governance matters, board composition, committee service, director independence, executive compensation, equity awards, and shareholder voting items. The filing record also reflects the company’s status as a British Columbia registrant with securities listed on Nasdaq under the symbol ABCL.
AbCellera Biologics reported a net loss of $43.2M for the quarter ended March 31, 2026, slightly improved from $45.6M a year earlier. Revenue nearly doubled to $8.3M, driven by higher research fees, but remains modest relative to expenses.
Research and development spending rose to $46.7M as the company advanced internal programs ABCL635, ABCL575 and ABCL688. Sales, general and administrative costs fell to $12.3M, reflecting lower legal and overhead spending. AbCellera ended the quarter with $504.7M in cash, cash equivalents and marketable securities, providing a sizable runway despite increased cash use.
The company highlighted progress in its transition toward an internal clinical pipeline, including positive interim Phase 1 data for ABCL635 and ongoing Phase 2 enrollment, while continuing to rely on government contributions and a large securities portfolio to fund operations.
AbCellera Biologics Inc. reported first quarter 2026 results and highlighted positive interim Phase 1 data for its lead program ABCL635. Revenue rose to $8.3 million from $4.2 million in Q1 2025, while net loss narrowed slightly to $43.2 million or $(0.14) per share.
The company increased research and development spending to $46.7 million and reduced sales, general and administrative expenses to $12.3 million. AbCellera ended the quarter with approximately $655 million in total available liquidity, including $531 million in cash, cash equivalents and marketable securities and about $124 million in non‑dilutive government funding.
Interim Phase 1 data for ABCL635, a potential first‑in‑class antibody targeting NK3R for menopausal vasomotor symptoms, showed a favorable tolerability profile with no serious adverse events or liver toxicity, an estimated half‑life of about 24 days supporting once‑monthly dosing, and strong, sustained suppression of testosterone, follicle‑stimulating hormone and luteinizing hormone as biomarkers of target engagement. These findings supported advancing ABCL635 into a Phase 2 trial in postmenopausal women, with topline efficacy data expected in Q3 2026.
AbCellera Biologics Inc. shareholders were notified that Baker Bros. Advisors and affiliated reporting persons beneficially own 33,012,138 common shares, equal to 10.8% of outstanding common stock based on 305,264,947 shares outstanding as of April 15, 2026. The disclosed position includes 2,736,200 shares issuable upon exercise of 27,362 European-style call options with a $0.20 strike that expire on June 12, 2026.
The filing is Amendment No. 2 to a Schedule 13G/A and states the Adviser has sole voting and dispositive power over the Fund-held shares under the management agreements; percentages are calculated under Rule 13d-3.
AbCellera Biologics Inc. will hold its 2026 Annual Meeting of Shareholders virtually on June 11, 2026, at 9:00 a.m. Pacific Time, with 305,264,947 common shares entitled to vote as of April 15, 2026.
Shareholders are asked to elect two class III directors, ratify Ernst & Young LLP as independent auditor for 2026, and approve on an advisory basis the compensation of named executive officers. AbCellera uses majority voting for uncontested director elections and provides online, telephone, and mail voting.
The company highlights progress toward becoming a clinical-stage biotech, including advancing ABCL635 and ABCL575 into trials, nominating additional candidates, and ending 2025 with about $700 million in available liquidity. The proxy also details board independence, committee structures, director and executive pay programs, a clawback policy, and prohibitions on hedging company shares.
Thermopylae Holdings Ltd., a 10% owner of AbCellera Biologics Inc., bought 38,000 common shares in an open-market purchase at a weighted-average price of $3.44 per share, with individual trade prices ranging from $3.42 to $3.45.
After this transaction, Thermopylae Holdings directly owns 56,134,097 AbCellera common shares, reinforcing its already significant stake in the company.
Thermopylae Holdings Ltd., a major shareholder of AbCellera Biologics Inc., reported an open-market purchase of 177,457 common shares at a weighted-average price of $3.27 per share. The filing notes the trades occurred in multiple transactions between $3.19 and $3.40, bringing Thermopylae’s holdings to 56,096,097 common shares.
AbCellera Biologics Inc. Chief Financial Officer Andrew Booth reported an open-market purchase of common shares. He bought 42,600 common shares at a price of $3.42 per share, increasing his direct holdings to 195,600 common shares following the transaction. The filing also reports 130,959 common shares held indirectly through his spouse.
AbCellera Biologics Inc. is a clinical-stage biotechnology company focused on first-in-class antibody medicines for high unmet medical needs. The company has two internal drug candidates in human trials: ABCL635 for menopausal vasomotor symptoms in a Phase 1/2 study, with topline data anticipated in Q3 2026, and ABCL575 for atopic dermatitis in a Phase 1 trial, with topline data expected in Q4 2026. Two additional candidates, ABCL688 for autoimmune disease and ABCL386 for oncology, are in IND-enabling activities, with first Phase 1/2 trials anticipated in 2027. AbCellera has invested about $1 billion over nearly 15 years to build an integrated antibody discovery, development, and 130,000-square-foot clinical manufacturing platform, supported by CAD $475.6 million in non-dilutive government funding. As of December 31, 2025, the company reports approximately $700 million in available liquidity and expects to fund operations beyond the next three years while continuing to generate losses in the near-to-medium term. Its portfolio includes 104 partner-initiated programs with downstream milestones and royalties, and 19 molecules that have reached the clinic, giving it diversified long-term exposure to potential commercial antibody drugs.
AbCellera Biologics Inc. reported full-year 2025 revenue of $75.1 million, up sharply from $28.8 million in 2024, while remaining loss-making as it ramps internal R&D. Net loss was $146.4 million, or $(0.49) per share, improving from a $162.9 million loss, or $(0.55) per share, in 2024.
Research and development expenses rose to $186.8 million as the company emphasized its own pipeline, while SG&A declined slightly to $83.2 million. Fourth-quarter 2025 revenue was $44.9 million, mostly from an upfront patent litigation settlement, with a quarterly net loss of $8.9 million, or $(0.03) per share.
The company highlighted its transition to a clinical-stage biotech, with ABCL635 moving into the Phase 2 portion of a Phase 1/2 trial and ABCL575 in a Phase 1 trial. Two additional candidates, ABCL688 and ABCL386, entered IND/CTA-enabling activities. As of December 31, 2025, AbCellera reported $561 million in cash, cash equivalents, and marketable securities plus about $135 million in available non-dilutive government funding, for roughly $700 million of total liquidity to support its strategy and planned clinical milestones.